Patients with advanced gastric or gastroesophageal adenocarcinoma need more efficacious and safer treatments than established today. S-1, a contemporary oral fluoropyrimidine, can provide that advantage.
INTRODUCTION
Gastric adenocarcinoma is frequent in Asia, South America, Eastern Europe, and in former Soviet Union, accounting for more than 800,000 new cases per year worldwide and it is the second most common cause of cancer death. 1, 2 Since an early detection strategy is rarely practiced except in Japan and Korea, gastric adenocarcinoma is often diagnosed in an advanced stage. Metastatic gastroesophageal adenocarcinoma is an incurable condition and little progress has been made in its treatment. Considering the degree of its health care burden, only a few randomized trials have been completed in an attempt to improve patient outcome. In general, cisplatin and fluoropyrimidine are the most frequently prescribed agents to treat advanced gastric adenocarcinoma and this combination has been studied in most of the recently completed phase III clinical trials. [3] [4] [5] [6] [7] Most regulatory agencies consider the combination of cisplatin/infusional fluorouracil as a reference for comparison with newer treatments. However, this combination is plagued with considerable adverse effects and inconveniences. 6 The combination of cisplatin and S-1 is more efficacious than single agent S-1. 8 In the palliative setting of advanced gastric or gastroesophageal adenocarcinoma, it is highly desirable that treatments reduce symptoms and prolong survival but also prove convenient and safe.
JOURNAL OF CLINICAL ONCOLOGY
S-1 is a fourth generation oral fluoropyrimidine approved in Japan, Korea, Singapore, and China for the treatment of advanced gastric adenocarcinoma and in Japan and Korea for adjuvant therapy of gastric adenocarcinoma after a curative resection. 9 S-1 contains tegafur/gimeracil/oteracil potassium in a molar ratio of 1.0:0.4:1.0. Beneficial effect of gimeracil in prolonging the half-life of fluorouracil and that of oteracil in improving gastrointestinal tolerability have been documented.
10,11 S-1 is noninferior to infusional fluoropyrimidine for efficacy against advanced gastric adenocarcinoma. 3 The metabolic rate of conversion of the oral prodrug, tegafur, to fluorouracil seems to differ in various ethnic populations, [12] [13] [14] therefore, a phase I trial was conducted in the western patients to establish the maximum tolerated dose of S-1 with cisplatin. 15 Using the western dose of S-1 with cisplatin, the combination was studied in a multicenter phase II study of untreated, advanced gastric or gastroesophageal adenocarcinoma patients and its efficacy and safety were considered encouraging. 16, 17 With the hypothesis that S-1 in cisplatin/ S-1 could improve overall survival, safety, and convenience compared to cisplatin/infusional fluorouracil, a non-Asian global phase III trial was initiated in March 2005.
PATIENTS AND METHODS

Patients
Chemotherapy-naïve patients with histologically confirmed, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma were eligible. In addition, patients were required to have the following: measurable or evaluable lesion, ability to take medications orally, age Ն 18 years, performance status of 0 or 1 by the Eastern Cooperative Oncology Group criteria, adequate liver, kidney, and bone marrow functions. Patients were excluded if they had serious comorbid conditions that could interfere with protocol therapy or protocol compliance. Several other but standard inclusion and exclusion criteria were implemented. The institutional review board for each participating institution approved the study protocol. All patients gave written informed consent.
Trial Design
By using 1:1 randomization, patients were randomly assigned to one of the two treatment arms and stratified by the extent of disease (locally advanced, one metastatic site or Ն 2 metastatic sites), prior adjuvant therapy, measurable versus nonmeasurable disease, and center. Twenty-four countries and 146 centers in the United States, Eastern and Western Europe, South America, Australia, and ex-Soviet Union block of nations participated in this trial.
S-1 was provided by Taiho (Princeton, NJ). The sponsor was made aware of the results through a Clinical Research Organization (Quintiles, Washington, DC). The sponsor contributed to the study design and has reviewed and approved this manuscript. The data collection, analysis, and interpretation were done independently (United BioSource Corporation, Newtown, PA). The authors have written the manuscript.
Pretreatment Evaluation
Medical history and physical findings were documented in each patient. Each patient also had an ECG, computed tomography of the abdomen and pelvis (and thorax, if needed), serum chemistry and CBC, and urine analysis.
Treatments
In the cisplatin/S-1 arm, S-1 was administered orally at 50 mg/m 2 divided in two daily doses for 21 days and cisplatin was administered at 75 mg/m 2 intravenously in 1 to 3 hours every 28 days. In the cisplatin/infusional fluorouracil arm, fluorouracil was administered at 1,000 mg/m 2 /24 hours as a 120-hour infusion and cisplatin at 100 mg/m 2 intravenously in 1 to 3 hours every 28 days. All patients received hydration and prophylactic standard medications to reduce toxic effects. Cisplatin was discontinued after 6 cycles in both arms and there was provision to continue S-1 or infusional fluorouracil until progression of disease or unacceptable toxic effects. Drug doses were reduced based on the predefined criteria.
Assessments During Treatment and Follow-Up
Toxicity assessments, compliance with S-1, and blood tests results were compiled after each cycle of treatment. Tumor assessments were carried out after every two cycles. Computed tomography was performed every 8 weeks until progression of cancer. Discontinuation of therapy occurred in the event of progression of disease, patient refusal, unacceptable toxicity, or death. Tumor status by imaging studies was assessed approximately every 2 months or until death.
Methods of Assessments
Toxicity was assessed by National Cancer Institute Common Toxicity Criteria for Adverse Events version 3.0 and response to treatment was assessed by the Response Evaluation Criteria in Solid Tumors (www.cancer.gov/). Radiographic evidence of response to treatment was also independently reviewed. An independent data monitoring committee oversaw the safety and efficacy data along with other aspects of the conduct of the study.
Sample Size and Other Stipulations
Sample size considerations were based on the survival end point. A 23.5% improvement in median survival from 8.5 months in the control arm to 10.5 months in the treatment arm, yielding a reduced hazard ratio of 0.81, was considered clinically relevant in this patient population. A total of 761 events (deaths) were required for a two-tailed unstratified log-rank test at the 5% significance and at least 80% power. Based on a patient accrual of 65 patients per month, a minimum follow-up of 12 months, and a loss to follow-up rate of 5%, a total of 1,050 patients were to be enrolled in the study to achieve the specified number of events in the scheduled follow-up time. Assuming that the study was not stopped at the planned interim analysis, the final survival analysis was to take place 12 months after the last patient was randomly assigned or the time that a total of 761 events (deaths) were observed, whichever was later. One interim analysis to test for early demonstration of potential inferior survival rate from the cisplatin/S-1 arm (one-sided test for inferiority) was planned (and performed). This analysis took place when 50% of the events (381 deaths) had been observed. A Lan-DeMets 18 spending function with an inferiority boundary that allowed for early stopping consistent with a onesided 0.025 O'Brien-Fleming design was assumed. 19 Overall survival (OS) time was defined from random assignment to the death date (any cause) of the patient. Alive patients were censored at the date last known to be alive. The final primary analysis of survival was conducted in the full analysis set (patients who received the assigned treatment), and included deaths collected up to 12 months after the last patient was randomly assigned. Patients having a documented survival status (alive or dead) after this date were censored at 12 months, the cutoff date. Progression-free survival was defined from random assignment to the earlier of date of first radiologic or clinical progression or date of death (from any cause). Alive patients without clinical or radiologic progressive disease were censored at their last tumor response assessment. Analysis of progression-free survival included deaths through December 31, 2007. This analysis was completed in March 2008.
RESULTS
Patient Characteristics
The flow chart of patients in this trial is shown in Figure 1 . Between May 18, 2005, and March 7, 2007, 1,305 patients were screened and 1,053 patients were randomly assigned and 1,029 (97.7%) were in the full analysis set. Five hundred twenty-one patients received cisplatin/S-1 (investigational arm) and 508 patients received cisplatin/infusional fluorouracil (control arm). All protocol violations at study entry were minor and occurred in 4.4% patients in the cisplatin/S-1 arm and 6.3% of patients in the cisplatin/infusional fluorouracil arm. Patient characteristics are presented in Table 1 . Only 1% of patients were Asian. The majority (95ϩ%) of patients on the study had metastatic disease and approximately 66% had at least two sites of metastases.
Treatment Characteristics
The median number of cycles received was four in both treatment arms. The median duration of protocol therapy was also the same in both arms-approximately 18 weeks. The median relative dose intensity (ratio of actual dose intensity to planned) was more than 0.90 in both arms. The most frequent reason for discontinuation of therapy was disease progression in both arms. More patients withdrew consent to continue therapy in the cisplatin/infusional fluorouracil arm (10.8%) than in the cisplatin/S-1 arm (6.5%).
Overall Survival
Data lock completed on March 7, 2008, the median survival of patients who received cisplatin/S-1 was 8.6 months and that of patients who received cisplatin/infusional fluorouracil was 7.9 months (log-rank P ϭ .20; hazard ratio [HR], 0.92; 95% CI, 0.80 to 1.05; Fig  2A) . Forest plot for survival by stratification factors is shown in Figure 3 ).
Overall Response
The overall confirmed independently reviewed response rate, a secondary end point, was 29.1% for the cisplatin/S-1 arm (n ϭ 402) and it was 31.9% for the cisplatin/infusional fluorouracil arm (n ϭ 385; Fisher's exact test p: 0.40). The median duration of response was 6.5 months in the cisplatin/S-1 arm (n ϭ 117) and it was 5.8 months in the cisplatin/infusional fluorouracil arm (n ϭ 123; log-rank P ϭ .08; HR, 0.77; 95% CI, 0.57 to 1.03).
Progression-Free Survival
The progression-free survival was 4.8 months (95% CI, 4.0 to 5.5 months) in the cisplatin/S-1 arm (n ϭ 521) and 5.5 months in the cisplatin/infusional fluorouracil arm (95% CI, 4.4 to 5.8 months) (n ϭ 508; log-rank P ϭ .92; HR, 0.99; 95% CI, 0.86 to 1.14; Fig 2B) .
Time to Treatment Failure
The median time-to treatment failure in both arms was 3.8 months, but overall, it was significantly in favor of cisplatin/S-1 compared to cisplatin/infusional fluorouracil (log-rank P ϭ .03; HR, 0.87; 95% CI, 0.77 to 0.99; Fig 2C) .
Second-Line Therapy
Twenty-nine point six percent of patients in the cisplatin/S-1 arm and 33.3% of patients in the cisplatin/infusional fluorouracil arm received second-line chemotherapy. The most frequently used agent was a fluoropyrimidine.
Toxic Effects
In the cisplatin/S-1 arm, 34 (6.5%) of patients withdrew consent compared to 55 (10.8%) in the cisplatin/infusional fluorouracil arm. At least one treatment-related serious adverse event was significantly more frequent in the cisplatin/infusional fluorouracil arm (29.7%) than in the cisplatin/S-1 arm (20.5%; P Յ .05). Treatment-related deaths were significantly more common in the cisplatin/infusional fluorouracil arm (4.9%) than in the cisplatin/S-1 arm (2.5%; Fisher's exact two-tailed P Յ .05).
Hematologic adverse events were more frequent in the cisplatin/ infusional fluorouracil arm than in the cisplatin/S-1 arm with neutropenia, thrombocytopenia, and leucopenia being significantly more frequent ( Table 2 ). The rate of complicated neutropenia (14.4% v 5%; P Յ .01) and all neutropenia-related deaths (2.8% v 0.8%; P Յ .05) were significantly more frequent in the cisplatin/infusional fluorouracil arm compared with the cisplatin/S-1 arm.
Among nonhematologic adverse events, stomatitis (13.6% v 1.3%; P Յ .01), mucosal inflammation (8.1% v 0.8%; P Յ .01), 
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www.jco.org renal-related events (Ͻ0.05), and electrolyte imbalances (P Յ .01) were significantly more frequent in the cisplatin/infusional fluorouracil than in the cisplatin/S-1 arm (Table 2) . However, liver-related adverse events (P Յ .01) were significantly more frequent in the cisplatin/S-1 arm than in the cisplatin/infusional fluorouracil arm. We evaluated various types of toxic effects in various regions and found no differences in toxic events suggesting that the likelihood of patients being underdosed with S-1 in any particular region is nonexistent (data not shown).
DISCUSSION
In the face of limited progress against advanced, untreated gastric or gastroesophageal adenocarcinoma, the focus has shifted on making treatments more convenient and safer while aspiring to prolonged overall survival. Oral agents including S-1 offer convenience to the patients. In this study, the combination of cisplatin and S-1 proved to be much safer than the combination of cisplatin and infusional fluorouracil. The primary end point was not met and cisplatin/S-1 did not prolong overall survival of patients compared with that by cisplatin/infusional fluorouracil but the OS was similar in both arms. In another trial, S-1 has been documented to be noninferior to infusional fluorouracil. 3 In FLAGS, improved safety profile while not compromising efficacy of the patients is a desirable outcome. Cisplatin/S-1 could be considered a substitute for cisplatin/infusional fluorouracil as it eliminates the need for portable infusional devices and frequent visits to the treating center.
For patients who have near normal organ functions and have considerable physical endurance, a combination of cytotoxics results in a longer OS than that resulting from a single agent. 8 The safety profile of cisplatin/S-1 and its superiority over single agent S-1 make cisplatin/S-1 attractive for further development. The docetaxel-based three-drug combination approved in the United States/European Union (and many other regions) for the treatment of untreated patients with advanced gastric or gastroesophageal adenocarcinoma results in a high rate of complicated neutropenia and other serious adverse events, 6 therefore, the original regimen is rarely utilized and many modifications with a better safety profile are used. However, cisplatin/S-1 provides some advantage and has a manageable rate of complicated neutropenia and other toxicities are also less frequent. In addition, the risk of neutropenic death due to toxicity of cisplatin/S-1 is lower than another phase III trial 6 including cisplatin/infusional fluorouracil in this trial. Compared with capecitabine, that was demonstrated to be noninferior than infusion fluorouracil but not with improved safety, 7 S-1 provides considerable safety advantage. We note that many modifications of cisplatin/infusional fluorouracil exist and some have a reasonable safety profile but they cannot be used as a regulatory reference in a pivotal trial. Comparison of FLAGS result to any specific nonreference regimen yields little advantage.
It is acknowledged that the significantly higher rate of renalrelated adverse events observed in the cisplatin/infusional fluorouracil arm can be attributed to the administration of a higher dose of cisplatin (100 mg/m 2 ) than it was in the cisplatin/S-1 arm (75 mg/m 2 ). Two issues are worthy of clarification: the drug doses or schedule of administration of the cisplatin and fluorouracil combination in the control arm (that served as a regulatory reference) could not be modified in FLAGS because it was conducted for the purpose of registration of S-1 and cisplatin/S-1 with its lower dose of cisplatin (this was based on the phase I trial in the West 15 where the starting S-1 and cisplatin doses could not be escalated) and resultant lower rate of renal-related adverse events, provides considerable improved safety without compromising efficacy. Several safety advantages as a result of cisplatin/S-1 were in fluoropyrimidine-related toxicities.
Will the OS be longer if one were to administer cisplatin at a dose of 100 mg/m 2 in the cisplatin/S-1 arm? Will OS be longer from cisplatin/S-1 if one used a lower dose of cisplatin in the control arm? These answers are not known but it is likely that the safety advantage of the current cisplatin/S-1 regimen will be either diminished with higher dose of cisplatin in the cisplatin/S-1 arm or the modified control arm would be rejected by various regulatory agencies. We suggest that the emphasis should be on further developing cisplatin/S-1 with biologic agents.
In this non-Asian trial, the Western-derived dose was studied. 15 The analysis of toxic events and treatment-related deaths by region suggests that the intensity of toxicity was similar in all regions suggesting patients in certain regions were not underdosed. Tolerance of capecitabine is thought to be different in North America versus Europe and it is speculated that folic acid levels in diet may be responsible for these differences, 20 however, no such data are available for S-1. The median survival durations for arms in this trial are somewhat but not substantially lower than other recent trials, 6, 8 however, the reason may be related to patient selection, burden of cancer, practice culture in different regions, continued patient access to health care, and experience of treating investigators. Compared with the SPIRITS (S-1 Plus cisplatin versus S-1 In RCT In the Treatment for Stomach cancer) trial, the median survivals in FLAGS are shorter. In SPIRITS trial, only 65% of patients had metastatic disease and 74% of patients received second-line therapy. The SPIRITS trial was conducted in Japan where the investigators are highly experienced and infrastructure is excellent. In FLAGS, 96% of patients had metastatic disease and only 31% received second-line therapy. FLAGS was a global trial where not only median survival differed by region but infrastructure and the experience of investigators varied considerably. Survival was longer in the region where the study treatment was given for longer time.
Considerably more progress is needed to improve the OS of patients with advanced, untreated gastric or gastroesophageal adenocarcinoma. Perhaps with the addition of biologic targeted agents, we should anticipate prolongation of OS of these patients as has been witnessed in patients with advanced, untreated colorectal cancers.
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Cisplatin/S-1 regimen provides a safe doublet platform to combine one or more biologic agents. Several ongoing or fully accrued phase III trials have incorporated a biologic agent and results are pending.
In conclusion, in patients with advanced, untreated gastric or gastroesophageal adenocarcinoma, cisplatin/S-1 and cisplatin/infusional fluorouracil resulted in similar OS; however, cisplatin/S-1 resulted in significantly reduced rates of severe adverse events and treatment-related deaths. Cisplatin/S-1 can be a substitute for cisplatin/infusional fluorouracil.
